Skip to main content

Prodrug Approaches of Nucleotides and Oligonucleotides

Buy Article:

$63.00 plus tax (Refund Policy)


The main threshold for the therapeutic applications of nucleotides and oligonucleotides is theirionic structure which implies poor cellular uptake and unfavorable pharmacokinetic parameters. To circumventthese problems, the anionic phosphate moieties may be temporarily masked with enzymolabile protectinggroups to form neutral pronucleotides or pro-oligonucleotides. In cells, enzymes cleave the protecting groupsand release the parent drug. Several prodrug strategies have been developed, but the kinetics and mechanismsof the deprotection of potential prodrug candidates are still often poorly known. The purpose of the presentreview is to summarize the current knowledge on the chemical aspects of alternative prodrug strategies atnucleotide and oligonucleotide level.

Keywords: Bis(POM)-Nucleotides; Cyclic Phosphoramidate Pronucleotides; Protecting Groups; S-Acyloxymethyl; nucleotide prodrug; short interfering RNAs

Document Type: Research Article


Affiliations: Department of Chemistry,University of Turku, FI-20014 Turku, Finland.

Publication date: December 1, 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more